TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01876615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808
Description: experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Depain tablet 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Depain tablet 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Depain tablet 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Depain tablet 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Depain tablet 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Depain tablet 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808+Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808+Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808+Diclofenac
Study: NCT03013985

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glulisine Insulin
Description: Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glulisine Insulin
Description: Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
Study: NCT01876615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808+Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808+Diclofenac
Study: NCT02801370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mg ciprofloxacin
Description: Single administration of OTO-201

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Simulated, single adminstration
Study: NCT01876615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH4808+Diclofenac
Study: NCT02635178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment
Description: Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Health Education Training
Description: The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
Study: NCT03276845

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound of the breast
Description: Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
Study: NCT00441363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine Mesylate
Description: 0.8 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bromocriptine Mesylate
Description: 0.8 mg tablet
Study: NCT01501032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-logic artificial pancreas system
Description: The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
Study: NCT01362023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: In 3 academic years, the intervention program consisted of three components:~1. Classroom practice by HPA to highlight healthy lifestyle habits~2. Teaching practice by HPA using books designed to include the nutritional objectives~3. Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~1. Experimental development of activities regarding each healthy lifestyle habit~2. Assessment of activity performed in classroom~3. An activity developed for use at home
Study: NCT05430685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: Intervention and placebo group each received a bottle of 60 capsules. Subjects were instructed to take one capsule in the morning and 1 capsule in the evening. Intervention group was getting 350 mg ashwagandha root extract per capsule (or 700 mg per day). Each intervention capsule delivered 2.5 mg withanolides with equivalence of 2,700 mg dry herb.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo group received the same type of bottle with similar looking capsules. Each person in the placebo group was instructed to take 1 capsule twice a day (2 capsules total). Capsules were filled with glycerin to the same weight as ashwagandha. Capsules were indistinguishable from each other.
Study: NCT01483456

Intervention type: OTHER
Group type: OTHER
Intervention: The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)
Description: The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~1. Identification of patient's fall risk,~2. Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~3. Get up workshop and morbidity and mortality conferences related to fall cases
Study: NCT04818723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: We wanted to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)
Study: NCT02510703

Intervention type: OTHER
Group type: OTHER
Intervention: Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)

Intervention type: OTHER
Group type: OTHER
Intervention: Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)
Study: NCT01768923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SDAI remission
Description: SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score \[SDAI\] \<3.3)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal disease activity remission
Description: Minimal disease activity group aims at minimal disease activity (DAS28\<2.6) (minimal disease activity group)
Study: NCT00910117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab 400 mg d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF regimen (cisplatin and 5-FU)
Description: cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
Study: NCT03518398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light
Description: E\> Eye (E-SWIN, Paris, France) IPL machine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: warm compression, lid scrub and non-preservative ocular lubricants

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: warm compression, lid scrub and non-preservative ocular lubricants
Study: NCT02061644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
Study: NCT01758042

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haploidentical Bone Marrow/Kidney
Description: Combined bone marrow and kidney transplantation using a haploidentical donor.
Study: NCT03884270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: 7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
Study: NCT04100655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-ß estradiol
Description: A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-ß estradiol
Description: A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
Study: NCT01304290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic/normoglycemic clamp
Description: Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours.
Study: NCT01957839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabergoline treatment
Description: cabergoline treatment for hyperprolactinemia group
Study: NCT02528617

Intervention type: DRUG
Group type: OTHER
Intervention: Velaglucerase alfa
Description: Enzyme replacement therapy
Study: NCT03872817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention ProLiSMentAl
Description: Using different methods and pedagogical techniques, mental health literacy psychoeducational intervention called ProLiSMentAl consist of 4 sessions of 90 minutes: 1) improvement social anxiety recognition; 2) prevention strategies; 3) self-help strategies; 4) knowledge of first aid strategies and 5) knowledge of professionals and treatments available.
Study: NCT04063995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
Study: NCT02474355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T790M+ Testing
Description: If a previous lab report is unavailable, the patient will need to have T790M+ testing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline Visit Blood & Urine Testing
Description: Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline ECG
Description: ECG to ensure absence of any cardiac abnormality

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visual Slit-Lamp Testing
Description: Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 Dosing
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Study: NCT03685500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symtuza® (TAF/FTC/DRV/c)
Description: Treatment with TAF/FTC/DRV/c during 8 weeks since randomized

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)
Description: Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
Study: NCT04605926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EQ001
Description: itolizumab \[Bmab600\]

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: EQ001 Placebo
Description: EQ001 Placebo
Study: NCT04688606

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cell capture technology
Description: CTCBIOPSY® automatic testing platform
Study: NCT01859871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website Intervention
Description: Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
Study: NCT01601067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Prolonged Exposure Therapy
Description: Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seeking Safety
Description: Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
Study: NCT00596453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin hydrochloride
Description: 250 mg Ciprofloxacin hydrochloride twice a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 14 days
Study: NCT01527708

Intervention type: PROCEDURE
Intervention: Corneal Collagen Cross-linking (CXL)
Description: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
Study: NCT03310892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic message
Description: Generic message

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored message
Description: Tailored message
Study: NCT04104997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops
Study: NCT00521859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloretazine
Description: 800 mg/m\^2 by vein daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 by vein daily x 5 Days
Study: NCT04104997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GLH8NDE
Description: 5% GLH8NDE as eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo as eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo as eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo as eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo as eye drops
Study: NCT04468815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Tablet
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Tablet
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 Tablet
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278 suspension
Description: Specified dose on specified days
Study: NCT00533559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT04229056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive rehabilitation (CBCR)
Description: CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General computer-based cognitive stimulation
Description: For this trial we have developed a webpage for cognitive sham-training, which is designed to provide general computer-based cognitive stimulation.
Study: NCT02217800

Intervention type: DRUG
Group type: OTHER
Intervention: saline
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.

Intervention type: DRUG
Group type: OTHER
Intervention: DG3173
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.

Intervention type: DRUG
Group type: OTHER
Intervention: octreotide
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
Study: NCT03750526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rTMS and AR
Description: rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS and AR
Description: Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AR
Description: AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
Study: NCT01633476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valaciclovir
Description: 2g q.d.s. orally for 6 months (dose adjusted according to renal function)
Study: NCT00912145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
Study: NCT00554645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-disciplinary group intervention
Description: children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional information
Description: 1 session of nutritional advise for parents and child and 1 follow-up after one month
Study: NCT00447044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: essential amino acids
Description: Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
Study: NCT01310699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympus Colonoscope CFHQ190AL
Description: Technically improved colonoscope with close focus high definition narrow band imaging.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Olympus Colonoscope CFHQ190AL
Description: Technically improved colonoscope with close focus high definition narrow band imaging.